Genentech announces favorable results for MS drug ocrelizumab
Swiss pharmaceutical company Genentech a member of the Roche Group, has released (at the European Committee for Treatment and Research in Multiple Sclerosis meeting) findings from Phase III clinical trials for its multiple ...